Patent US4916213A successfully refreshed from Google Patents.
US4916213A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Ribosomal inhibiting protein-immunoglobulin conjugates with specificity for tumor cell surface antigens, and mixtures thereof
Assignee: Xoma Royalty Corp
•
Filing: 1988-06-08
•
Granted: 1990-04-10
•
Expires: 2008-06-08
Abstract
Abstract Novel compositions and methods are provided for the treatment of cancer employing monoclonal antibodies (MoAbs) conjugated to a toxin. According to the present invention, MoAbs defining epitopes on either a tumor associated glycoprotein antigen of about 72 kD m.w. or on carcinoembryonic antigen conjugated to a ribosomal inhibiting protein, or the like, are employed either alone or in combination as cytotoxic agents in the treatment of various cancers including, but not limited to, colorectal carcinoma, ovarian carcinoma and osteogenic sarcoma. Hydridomas XMMCO-791 and XMMCO-228 were deposited with the A.T.C.C. on Aug. 14, 1986 and given A.T.C.C. Accession Nos. HB 9173 and HB 9174, respectively.
Inventors
- 👤 Patrick J. Scannon
- 👤 Robert W. Baldwin
- 👤 Vera S. Byers
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-31 12:17
CPC Classifications
C; C07; C07K; C07K16/00; C07K16/18; C07K16/28; C07K16/30; A; A61; A61K; A61K47/00; A61K47/50; A61K47/51; A61K47/68; A61K47/6801; A61K47/6803; A61K47/6811; A61K47/6817; A61K47/6819; A61K47/6825; A61K47/6827; A61K47/6835; A61K47/6851; A61K51/00; A61K51/02; A61K51/04; A61K51/08; A61K51/10; A61K51/1045; A61K51/1063; C07K16/3046; A61K2123/00; A61K38/00; C07K2317/00; C07K2317/70; C07K2317/73; C07K2317/734; Y; Y10; Y10S; Y10S530/00; Y10S530/806; Y10S530/808; Y10S530/827; Y10S530/828
Claims Analysis
Total Claims: 32
Claim 1
Independent Claim
56 words
A pharmaceutical composition comprising an immunotoxin consisting essentially of a ribosomal inhibiting toxin conjugated to a monoclonal antibody that binds to an epitope on a non-shedding membrane-bound human osteogenic sarcoma tumor associated antigen of about 72 kD m.w., and which has the binding specificity of antibodies produced by hybridoma XMMCO-791 having A.T.C.C. Accession No. HB 9173.
Claim 2
Dependent Claim
56 words
A pharmaceutical composition comprising an immunotoxin consisting essentially of a ribosomal inhibiting toxin conjugated to a monoclonal antibody that binds to an epitope on a non-shedding membrane-bound human osteogenic sarcoma tumor associated antigen of about 72 kD m.w., and which has the binding specificity of antibodies produced by hybridoma XMMCO-791 having A.T.C.C. Accession No. HB 9173.
Claim 3
Dependent Claim
20 words
The composition according to claim 1 wherein the immunoglobulin is produced by hybridoma XMMCO-791 having A.T.C.C. Accession No. HB 9173.
Claim 4
Dependent Claim
56 words
A pharmaceutical composition comprising an immunotoxin consisting essentially of a ribosomal inhibiting toxin conjugated to a monoclonal antibody that binds to an epitone on a carcinoembryonic antigen of about 180 kD m.w. present on human colon carcinoma cells, and which has the binding specificity of antibodies produced by hybridoma XMMCO-228 having A.T.C.C. Accession No. HB 9174.
Claim 5
Dependent Claim
56 words
A pharmaceutical composition comprising an immunotoxin consisting essentially of a ribosomal inhibiting toxin conjugated to a monoclonal antibody that binds to an epitone on a carcinoembryonic antigen of about 180 kD m.w. present on human colon carcinoma cells, and which has the binding specificity of antibodies produced by hybridoma XMMCO-228 having A.T.C.C. Accession No. HB 9174.
Claim 6
Dependent Claim
20 words
The formulation according to claim 3, wherein the immunoglobulin is produced by hybridoma XMMCO-228 having A.T.C.C. Accession No. HB 9174.
Claim 7
Dependent Claim
24 words
The composition according to claims 1 or 3, wherein the ribosomal inhibiting protein is a lectin A chain purified with anti-lectin B chain antibodies.
Claim 8
Dependent Claim
21 words
The composition according to claim 5, wherein the lectin A chain is ricin A chain purified with anti-ricin B chain antibodies.
Claim 9
Dependent Claim
21 words
The composition according to claim 5, wherein the lectin A chain is abrin A chain purified with anti-abrin B chain antibodies.
Claim 10
Dependent Claim
111 words
A cytotoxic therapeutic cocktail comprising a mixture of: a first immunotoxin consisting essentially of a ribosomal inhibiting toxin conjugated to a monoclonal antibody that binds to an epitope on a non-shedding human osteogenic sarcoma tumor associated antigen of about 72 kD m.w., which has the binding specificity of antibodies produced by hybridoma XMMCO-791 having A.T.C.C. Accession No. HB 9173; and a second immunotoxin consisting essentially of a ribosomal inhibiting toxin conjugated to monoclonal antibody that binds to an epitope on a carcinoembryonic antigen of 180 kD m.w. present on human colon carcinoma cells, and which has the binding specificity of antibodies produced by hybridoma XMMCO-228 having A.T.C.C. Accession No. HB 9174.
Claim 11
Dependent Claim
111 words
A cytotoxic therapeutic cocktail comprising a mixture of: a first immunotoxin consisting essentially of a ribosomal inhibiting toxin conjugated to a monoclonal antibody that binds to an epitope on a non-shedding human osteogenic sarcoma tumor associated antigen of about 72 kD m.w., which has the binding specificity of antibodies produced by hybridoma XMMCO-791 having A.T.C.C. Accession No. HB 9173; and a second immunotoxin consisting essentially of a ribosomal inhibiting toxin conjugated to monoclonal antibody that binds to an epitope on a carcinoembryonic antigen of 180 kD m.w. present on human colon carcinoma cells, and which has the binding specificity of antibodies produced by hybridoma XMMCO-228 having A.T.C.C. Accession No. HB 9174.
Claim 12
Dependent Claim
27 words
The cytotoxic cocktail according to claim 8, wherein the monoclonal antibody of the first immunotoxin is that produced by hybridoma XMMCO-791 having A.T.C.C. Accession No. HB 9174.
Claim 13
Dependent Claim
27 words
The cytotoxic cocktail according to claim 9, wherein the monoclonal antibody of the second immunotoxin is that produced by hybridoma XMMCO-228 having A.T.C.C. Accession No. HB 9174.
Claim 14
Dependent Claim
23 words
The cytotoxic cocktail according to claim 8, wherein the ribosomal inhibiting protein is a lectin A chain purified with anti-lectin B chain antibodies.
Claim 15
Dependent Claim
22 words
The cytotoxic cocktail according to claim 11, wherein the lectin A chain is ricin A Chain purified with anti-ricin B chain antibodies.
Claim 16
Dependent Claim
22 words
The cytotoxic cocktail according to claim 11, wherein the lectin A chain is abrin A Chain purified with anti-abrin B chain antibodies.
Claim 17
Dependent Claim
45 words
The cytotoxic cocktail according to claim 11, wherein the lectin A chain of the first conjugate is ricin A chain purified with anti-ricin B chain antibodies and the lectin A chain of the second conjugate is abrin A chain purified with anti-abrin B chain antibodies.
Claim 18
Dependent Claim
44 words
A method for the treatment of cancer cells selected from the group consisting carcinoma and sarcoma type cancer cells, comprising administering a therapeutic dose of a pharmaceutical composition according to claim 1 to a cancer cell host wherein said cells express the defined epitope.
Claim 19
Dependent Claim
44 words
A method for the treatment of cancer cells selected from the group consisting carcinoma and sarcoma type cancer cells, comprising administering a therapeutic dose of a pharmaceutical composition according to claim 3 to a cancer cell host wherein said cells express the defined epitope.
Claim 20
Dependent Claim
44 words
A method for the treatment of cancer cells, selected from the group consisting carcinoma and sarcoma type cancer cells, comprising administering a therapeutic dose of the cytotoxic cocktail according to claim 8 to a cancer cell host wherein said cells express the defined epitope.
Claim 21
Independent Claim
39 words
The method for the treatment of cancer cells according to either of claims 15 or 16, wherein the therapeutic dose of the cytotoxic conjugate is approximately 0.01 mg to 20.0 mg per kg of host body weight per day.
Claim 22
Independent Claim
39 words
The method for the treatment of cancer cells according to either of claims 15 or 16, wherein the therapeutic dose of the cytotoxic conjugate is approximately 0.05 mg to 5.0 mg per kg of host body weight per day.
Claim 23
Dependent Claim
35 words
The method for the treatment of cancer cells according to claim 17, wherein the therapeutic dose of the cytotoxic conjugates is approximately 0.01 mg to 20.0 mg per kg of host body weight per day.
Claim 24
Dependent Claim
35 words
The method for the treatment of cancer cells according to claim 17, wherein the therapeutic dose of the cytotoxic conjugates is approximately 0.05 mg to 5.0 mg per kg of host body weight per day.
Claim 25
Independent Claim
25 words
The method for the treatment of cancer cells according to any of claims 15, 16, or 17, wherein the cancer cells are colon carcinoma cells.
Claim 26
Independent Claim
25 words
The method for the treatment of cancer cells according to any of claims 15, 16, or 17, wherein the cancer cells are ovarian carcinoma cells.
Claim 27
Dependent Claim
20 words
The method for the treatment of cancer cells according to claim 15, wherein the cancer cells are osteogenic sarcoma cells.
Claim 28
Dependent Claim
19 words
Hybridoma XMMCO-228 having A.T.C.C. Accession No. HB 9174 which produces an immunoglobulin that defines an epitope on carcinoembryonic antigen.
Claim 29
Dependent Claim
19 words
Hybridoma XMMCO-228 having A.T.C.C. Accession No. HB 9174 which produces an immunoglobulin that defines an epitope on carcinoembryonic antigen.
Claim 30
Dependent Claim
19 words
A kit for the treatment of cancer cells, comprising compositions according to any of claims 1, 3 or 8.
Claim 31
Dependent Claim
17 words
A method according to claim 15, 16 or 19 wherein the cancer cell host is a human.
Claim 32
Dependent Claim
22 words
The cytotoxic cocktail according to claim 8, wherein the first immunotoxin and second immunotoxin are each present at about 50% by weight.
References Cited (Backward Citations)
US4146603A
Cited
US4172124A
Cited
US4340535A
Cited
US4350626A
Cited
US4349528A
Cited
US4414148A
Cited
US4590071A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1993-04-09 | 1993-10-09 | 1994-04-10 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1997-04-09 | 1997-10-09 | 1998-04-10 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2001-04-09 | 2001-10-09 | 2002-04-10 | $7700.00 | Window Closed / Lapsed |